Literature DB >> 35475011

Bilobectomy for synchronous multiple lung cancer after COVID-19 pneumonia: a case report.

Fumihiro Ishibashi1, Hironobu Wada1, Toshiko Kamata1, Jiro Terada2, Kenji Tsushima2, Yuichiro Hayashi3, Takayuki Shiomi3, Kenta Takahashi4, Tadaki Suzuki4, Shigetoshi Yoshida1.   

Abstract

Coronavirus disease 2019 (COVID-19) is a novel emerging disease and a major risk factor for postoperative complications, especially in thoracic surgery. However, it is unclear how previous COVID-19 infection may affect perioperative management of lung resection patients. A 70-year-old woman visited her primary doctor complaining of chest pain. Chest computed tomography (CT) revealed three abnormal nodules in the right upper and middle lung lobes and synchronous triple primary cancer was suspected. Before we could assess the patient for surgery, she developed a persistent fever. A second chest CT scan revealed newly emerged subpleural ground-glass opacities (GGO) in the right lung. The patient was diagnosed with COVID-19 pneumonia and hospitalized. She was treated for COVID-19 (Clinical Trial: jRCTs031200196) and discharged in a satisfactory condition 10 days later. A right upper and middle bilobectomy was performed 60 days after the patient's initial COVID-19 diagnosis without any complications. Histopathological examination of the nodules identified synchronous triple primary lung cancer. The subpleural right upper and middle lung lobe tissue showed peribronchial lymphocyte infiltration and interstitial thickening. However, immunohistochemical staining for the SARS-CoV-2 antigen and PCR testing for SARS-CoV-2 were both negative. In this case, bilobectomy for triple primary lung cancer was performed safely after COVID-19 pneumonia. Further studies are needed to establish a safe and appropriate perioperative management system for thoracic surgery in patients recovering from COVID-19 pneumonia. 2022 AME Case Reports. All rights reserved.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; case report; lung cancer; surgery

Year:  2022        PMID: 35475011      PMCID: PMC9010318          DOI: 10.21037/acr-21-65

Source DB:  PubMed          Journal:  AME Case Rep        ISSN: 2523-1995


  5 in total

1.  Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer.

Authors:  Pamela Samson; Aalok Patel; Tasha Garrett; Traves Crabtree; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-04-16       Impact factor: 4.330

2.  Lobectomy with pathological examination in lung cancer patients who recovered from COVID-19.

Authors:  Andrey Nefedov; Makhmud Mortada; Tatyana Novitskaya; Alexey Patsyuk; Andrey Kozak; Piotr Yablonskii
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-04-09

3.  Elective lung resection after treatment for COVID-19 pneumonia.

Authors:  Takashi Sakai; Yoko Azuma; Kotaro Aoki; Megumi Wakayama; Shion Miyoshi; Kazuma Kishi; Kazuhiro Tateda; Sakae Homma; Akira Iyoda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-04-03

4.  Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.

Authors:  Sufang Tian; Weidong Hu; Li Niu; Huan Liu; Haibo Xu; Shu-Yuan Xiao
Journal:  J Thorac Oncol       Date:  2020-02-28       Impact factor: 15.609

5.  Pulmonary Lobectomy After COVID-19.

Authors:  Alberto Testori; Gianluca Perroni; Emanuele Voulaz; Alessandro Crepaldi; Marco Alloisio
Journal:  Ann Thorac Surg       Date:  2020-09-25       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.